Business Context and Reporting Period
Company: Voyager Therapeutics, Inc. (VYGR)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2026
Business Overview: Voyager is a biotechnology company focused on developing genetic medicines for neurological diseases, including Alzheimer's disease (AD), Friedreich's ataxia, and Parkinson's disease. The company utilizes its proprietary TRACER™ AAV capsid discovery platform and the Voyager NeuroShuttle™ non-viral delivery platform. It has no product revenue and relies on collaboration agreements (e.g., Neurocrine, Novartis, Alexion) and equity financing.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Collaboration Revenue | $2,593 | $6,473 |
| Net Loss | $(27,937) | $(31,021) |
| Net Loss Per Share (Basic & Diluted) | $(0.47) | $(0.53) |
| Research & Development Expenses | $24,602 | $31,526 |
| General & Administrative Expenses | $8,261 | $9,640 |
| Cash, Cash Equivalents, & Marketable Securities | $171,669 | $196,447 |
| Accumulated Deficit | $(473,842) | $(357,205) |
Note: Cash, cash equivalents, and marketable securities for Q1 2025 calculated as $65,300 (Cash) + $131,147 (Marketable Securities) based on Dec 31, 2025 balance sheet context and Q1 2025 cash flow start/end logic, though exact Q1 2025 ending balance is $77,629 per cash flow statement.
Material Changes vs. Prior Period
- Revenue Decline: Collaboration revenue decreased by $3.9 million (60%) to $2.6 million, primarily due to lower recognition from the 2023 Neurocrine Collaboration Agreement ($1.3M vs $4.5M in Q1 2025).
- Expense Reduction: Total operating expenses decreased by $8.3 million. R&D expenses dropped $6.9 million due to the discontinuation of the SOD1 silencing gene therapy program, reduced spend on the VY7523 anti-tau antibody program following trial enrollment completion, and lower headcount. G&A expenses decreased $1.4 million due to lower legal fees and reduced personnel costs.
- Net Loss Improvement: Net loss narrowed by $3.1 million to $27.9 million, driven by the reduction in operating expenses.
- Capital Raise: The company raised $3.0 million in net proceeds through an at-the-market (ATM) equity offering during the quarter.
Outlook, Guidance, and Risks
Management Commentary & Pipeline Updates
- VY1706 (Tau Silencing Gene Therapy): Completed GLP toxicology in Q1 2026. Anticipates completing the IND application process in Q2 2026 and initiating a clinical trial in H2 2026.
- VY7523 (Anti-tau Antibody): Phase 1 multiple ascending dose (MAD) trial enrollment completed in Q4 2025. Initial tau PET imaging efficacy data expected in H2 2026.
- Neurocrine Collaboration: Neurocrine intends to initiate a clinical trial for NBIB-223 (Friedreich's ataxia) in H2 2026 pending FDA IND clearance.
- Liquidity: As of March 31, 2026, the company held $171.7 million in cash and marketable securities. Management expects these resources, combined with collaboration reimbursements and interest income, to fund operations into 2028.
Risks and Contingencies
- Novartis Agreement Termination: In October 2025, Novartis partially terminated the 2022 Option and License Agreement regarding two targets (effective Feb 1, 2026). Voyager is no longer eligible for milestones or royalties on these specific programs, though the agreement remains active for one remaining target.
- Financing Needs: The company has a history of losses and expects to continue incurring significant expenses. Future capital requirements depend on clinical trial progress and regulatory outcomes. Failure to raise additional capital could force delays or termination of programs.
- Forward-Looking Statements: Significant risks include the uncertainty of clinical trial results, regulatory approvals, and the ability to secure future funding.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $171.7 million cash balance against the projected burn rate into 2028, considering potential delays in clinical trials.
- Novartis Termination Impact: Assess the financial impact of the partial termination of the 2022 Novartis agreement and the status of the remaining target.
- Revenue Recognition: Monitor the variability of collaboration revenue, specifically the proportional performance model recognition from Neurocrine and Novartis agreements.
- Clinical Milestones: Track the timeline for the VY1706 IND submission (Q2 2026) and VY7523 data readout (H2 2026) as key value drivers.
- ATM Facility: Review the remaining capacity ($96.9 million) and utilization of the at-the-market sales agreement for future dilution risks.